表紙
市場調查報告書

受託製造服務契約:製藥開發平台的擴大推動的製造機會擴大

Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion

出版商 GlobalData 商品編碼 951732
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
受託製造服務契約:製藥開發平台的擴大推動的製造機會擴大 Contract Manufacturing Service Agreements - Rising Manufacturing Opportunities Driven by Pharmaceutical Pipeline Expansion
出版日期: 2020年07月30日內容資訊: 英文 51 Pages
簡介

本報告提供受託製造服務契約的相關調查,製造規模,各治療領域的受託服務契約,提供服務,主要的CMO企業的資訊等。

目錄

第1章 目錄

第2章 表格的清單

第3章 圖的清單

第4章 摘要整理

第5章 簡介

第6章 受託服務契約概要

第7章 受託服務和生產規模

  • API受託製造服務契約
  • 少量受託製造服務契約

第8章 各治療領域的受託服務契約

第9章 特殊產品範疇

第10章 各贊助商外包市值

第11章 CMO的成果

第12章 言及

  • 提供服務,生產規模,及CSA關係相關洞察
  • 主要的CMO企業
  • 贊助商的市值和外包的關係
  • 各種等級的公開資訊明確指示

第13章 關於調查手法的註釋

第14章 附錄

目錄
Product Code: GDPS0032MAR

This report is a brand new publication covering contract service agreements, across a range of different services and manufacturing scales. The number of contract service agreements secured serves as a primary indicator of a CMO's performance. Contract Manufacturing Service Agreements is critical for establishing an understanding of the overall CMO industry, the range of services provided and the features of some of the largest CMOs participating in the industry.

This report gives an important expert quantitative analysis on the contract manufacturing industry. Findings are based on the industry's most comprehensive databases of the CMO industry (GlobalData's Databases of Contract Service Providers and Deals) this analysis is primarily driven by the Deals Database, which is continuously updated and reveals manufacturing relationships for Pharma products and the types of services offered. The 14 figures and 5 tables throughout the report illustrate major points and trends.

Scope

This report is required reading for -

  • CMO executives who must have deep understanding of the novel approvals landscape to make strategic planning and investment decisions.
  • Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

  • Overview of CSAs and the levels of outsourcing associated with different services and drug type
  • Detailed view of CDMO performance by CSAs and an assessment of their CSAs manufacturing scale from GlobalData's Deals database
  • Manufacturing Agreements for different molecule types, RoA and by sponsor company market cap have all been assessed.
  • Analysis of regulatory designations such as those with Orphan, Breakthrough or Fast Track designations and assessment of outsourcing

Table of Contents

1 Table of Contents

2 List of Tables

3 List of Figures

4 Executive Summary

5 Introduction

6 Contract Service Agreements Overview

7 Contract Services Offered and Manufacturing Scale

  • 7.1 API Manufacturing Contract Service Agreements
  • 7.2 Dose Manufacturing Contract Service Agreements

8 Contract Service Agreements by Therapy Area

9 Special Product Categories

10 Outsourcing by Sponsor Market Cap

11 CMO Performance

12 What It Means

  • 12.1 Insights on Services Offered, Scale of Production, and CSA Relationships
  • 12.2 Top CMO Players
  • 12.3 Sponsor Market Cap Relationships to Outsourcing
  • 12.4 Varying Levels of Public Disclosure

13 Notes on Methodology

14 Appendix

  • 14.1 Appendix Tables
  • 14.2 Bibliography
  • 14.3 Primary Research - Key Opinion Leaders in this Report
  • 14.4 About the Authors
  • 14.5 Contact Us
  • 14.6 Disclaimer

List of Tables

List of Tables

  • Table 1: Contract Service Agreements Offering More than One Manufacturing Service, 2018-2020
  • Table 2: Scale of Therapy Area Contract Service Agreements, 2018-2020
  • Table 3: Sponsor Type by Services Offered in Contract Service Agreements, 201

List of Figures

List of Figures

  • Figure 1: Scale of Contract Service Agreements, 2018-2020
  • Figure 2: Contract Service Agreements by Year, January 2018 - March 2020
  • Figure 3: Quantity of Services Offered Per Contract Service Agreement, 2018-2020
  • Figure 4: Quantity of Drugs